ACCENTMICST Stock Price Today (NSE: ACCENTMIC)
Fundamental Score
ACCENTMICST Share Price — Live NSE/BSE Price, Fundamentals & Analysis
ACCENTMICST share price today is ₹267.00, up +0.00% on NSE/BSE as of 17 June 2026. ACCENTMICST (ACCENTMIC) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹826.06 (Cr). The 52-week high for ACCENTMIC share price is ₹324.00 and the 52-week low is ₹215.10. At a P/E ratio of 23.83x, ACCENTMIC is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 18.44% and a debt-to-equity ratio of 0.00.
ACCENTMICST Share Price Chart — NSE/BSE Historical Performance
ACCENTMICST share price chart: 9.65% return over the past month. 52-week high ₹324.00, 52-week low ₹215.10.
ACCENTMICST — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹272.00 | ₹273.00 | ₹267.00 | ₹267.00 | 5.50K (Cr) | |
| ₹271.20 | ₹274.00 | ₹267.55 | ₹271.00 | 5.50K (Cr) | |
| ₹275.00 | ₹277.55 | ₹271.00 | ₹271.55 | 8.50K (Cr) | |
| ₹276.50 | ₹278.00 | ₹268.00 | ₹277.55 | 21.00K (Cr) | |
| ₹271.80 | ₹279.00 | ₹268.00 | ₹275.40 | 9.00K (Cr) | |
| ₹275.00 | ₹278.00 | ₹269.50 | ₹274.55 | 18.50K (Cr) | |
| ₹269.00 | ₹284.30 | ₹268.20 | ₹283.55 | 51.00K (Cr) | |
| ₹259.00 | ₹270.80 | ₹253.00 | ₹270.80 | 44.50K (Cr) | |
| ₹264.90 | ₹267.00 | ₹253.75 | ₹257.95 | 10.50K (Cr) | |
| ₹274.00 | ₹280.00 | ₹255.10 | ₹256.90 | 41.00K (Cr) |
ACCENTMICST — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹248.00 | ₹284.30 | ₹238.00 | ₹267.00 | +7.66% | |
| ₹282.10 | ₹292.00 | ₹240.00 | ₹244.95 | -13.17% | |
| ₹312.50 | ₹320.00 | ₹278.25 | ₹284.15 | -9.07% | |
| ₹270.00 | ₹324.00 | ₹252.60 | ₹315.95 | +17.02% | |
| ₹231.50 | ₹275.50 | ₹215.10 | ₹266.00 | +14.90% |
AI Research Briefing
Powered by Gemini · 2026-04-22
Micro-cap API play with growth priced in; too risky for the return.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Accent Microcell's stock is currently Over the past month, the stock has seen a significant increase of 16.13%. There have been corporate announcements regarding updates and compliance reports on corporate governance filed with the exchange on April 6, 2026.
CORE STORY (THE REAL GAME)
Accent Microcell is being priced as a high-growth API (Active Pharmaceutical Ingredient) play, capitalizing on the broader Indian pharma sector's shift towards backward integration and export diversification. It's an SME (Small and Medium Enterprise) attempting to ride the 'Make in India' wave in pharmaceuticals.
- Sector tailwinds in Indian pharma
- Export growth and diversification
- Investments in API manufacturing
- Successful backward integration into APIs
- New export contracts
- Positive regulatory changes
- Micro-cap liquidity risk
- Fragile news sentiment
- Strong Sell analyst consensus
Promoter holding increased slightly (Δ 0.35%), but FII interest is negligible (Δ -0.01%). DII interest is small but growing (Δ 0.41%).
Indian pharma sector benefits from government support and a push for self-reliance.
Free Cash Flow 5Y is minimal at ₹0.24 Cr. Profitability not converting strongly to cash.
In the next 3-6 months, watch for execution on API integration and export growth. Failure to deliver will lead to a sharp correction.
Primary Thesis Risk
Failure to scale API production will crater the stock.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
ACCENTMICST Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
ACCENTMICST Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ACCENTMIC across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (18.44%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (23.66%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 23.83 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Consistent Growth Track Record (15.05% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (51.23% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (87.29x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (55.44%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Limited Institutional Interest (FII+DII: 3.29%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
ACCENTMICST vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare ACCENTMICST with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
ACCENTMICSTACCENTMICST...Selected✓ ACCENTMIC • | 60/100 | ₹267.00₹267 | ₹826.06₹826.06 | 23.83Average 23.8 Average | 18.44%Good 18.44% Good | 23.66%Excellent 23.66% Excellent | 0.00Excellent 0.0 Excellent | 51.23%Excellent 51.23% Excellent | 15.05%Excellent 15.05% Excellent | 0.29% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
ACCENTMICST PE Ratio History
Historical price-to-earnings ratio for ACCENTMIC — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2023 | ₹5.81 | ₹292.40 | 50.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
ACCENTMICST Dividend History
Annual cash dividends paid by ACCENTMIC — dividend yield 0.29%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2024 | ₹1.04 Cr |
| FY 2023 | ₹1.03 Cr |
| FY 2022 | ₹0.43 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
ACCENTMICST Quarterly Performance
Latest quarterly metrics for ACCENTMIC — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
10.58%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
9.71%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
15.05%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
51.23%
Compounded annual net profit growth over 5 years
ACCENTMICST Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ACCENTMIC — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
ACCENTMICST Financial Statements
Annual income statement, balance sheet and cash flow for ACCENTMICST (ACCENTMIC) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for ACCENTMICST
About ACCENTMIC (ACCENTMICST)
ACCENTMICST (ACCENTMIC) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current m...arket capitalisation of ₹826.06 (Cr). ACCENTMICST has delivered a Return on Equity (ROE) of 18.44% and a ROCE of 23.66%. The debt-to-equity ratio stands at 0.00, reflecting the company's capital structure. Investors tracking ACCENTMIC share price can monitor key metrics including P/E ratio, promoter holding of 55.44%, and quarterly earnings growth.
Company Details
ACCENTMIC Share Price: Frequently Asked Questions
What is the current share price of ACCENTMICST?
ACCENTMICST (ACCENTMIC) trades at ₹267.00 on NSE. Market cap ₹826.06 (Cr). Educational data only.
What is the P/E ratio of ACCENTMICST?
ACCENTMICST has a P/E of 23.83x vs industry average 31.77x.
What is the Bull Run score for ACCENTMICST?
ACCENTMICST has a Bull Run score of 60/100 based on 25+ financial parameters.
Does ACCENTMICST pay dividends?
ACCENTMICST has a dividend yield of 0.29%. Past dividends don't guarantee future payments.
What is the ROE of ACCENTMICST?
ACCENTMICST has ROE of 18.44%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of ACCENTMICST?
ACCENTMICST has debt-to-equity of 0.00.
Is ACCENTMICST a good investment?
Bull Run gives ACCENTMICST a score of 60/100. This is not investment advice — consult a SEBI-registered advisor.